Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of ADO09 vs Insulin Aspart in Type 1 Diabetes
NCT03981627Phase 2Completed
- Sponsor
- Adocia
- Start
- Jun 2019
- Primary completion
- Jun 2020
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ADO09 in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Adocia. Primary endpoint: Change in Area Under the Plasma Glucose Curve (0-4h). Started Jun 2019; status: completed.
02
Drugs
ADO09
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT03981627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03981627.